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Abstract
Plasmodium falciparum–infected erythrocytes bind endothelial receptors to sequester in vascular beds, and binding to
ICAM1 has been implicated in cerebral malaria. Binding to ICAM1 may be mediated by the variant surface antigen family
PfEMP1: for example, 6 of 21 DBLbC2 domains from the IT4 strain PfEMP1 repertoire were shown to bind ICAM1, and the
PfEMP1 containing these 6 domains are all classified as Group B or C type. In this study, we surveyed binding of ICAM1 to 16
DBLbC2 domains of the 3D7 strain PfEMP1 repertoire, using a high throughput Bioplex assay format. Only one DBL2bC2
domain from the Group A PfEMP1 PF11_0521 showed strong specific binding. Among these 16 domains, DBL2bC2PF11_0521
best preserved the residues previously identified as conserved in ICAM1-binding versus non-binding domains. Our analyses
further highlighted the potential role of conserved residues within predominantly non-conserved flexible loops in adhesion,
and, therefore, as targets for intervention. Our studies also suggest that the structural/functional DBLbC2 domain involved
in ICAM1 binding includes about 80 amino acid residues upstream of the previously suggested DBLbC2 domain.
DBL2bC2PF11_0521 binding to ICAM1 was inhibited by immune sera from east Africa but not by control US sera. Neutralizing
antibodies were uncommon in children but common in immune adults from east Africa. Inhibition of binding was much
more efficient than reversal of binding, indicating a strong interaction between DBL2bC2PF11_0521 and ICAM1. Our high
throughput approach will significantly accelerate studies of PfEMP1 binding domains and protective antibody responses.
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Introduction
The variant surface antigen Plasmodium falciparum erythrocyte
membrane protein 1 (PfEMP1) is a virulence factor of the human
malaria parasite P. falciparum. PfEMP1 variants are encoded by
about 60 var genes per parasite, and have been implicated in the
cytoadhesion of P. falciparum-infected erythrocytes (PE) to vascular
endothelium [1]. PE bind numerous receptors (reviewed in [2] and
[3]), including thrombospondin [4], CD36 [5], ICAM1 [6], E-
selectin and VCAM-1 [7], chondroitin sulfate A (CSA) [8,9],
complement receptor 1 [10], PECAM-1 [11], heparan sulfate
[12,13], bloodgroup sugars A and B [14], and the serum proteins
IgG/IgM and fibrinogen [15]. Cytoadhesion allows sequestration
of PE in deep vascular beds, prevents clearance of PE in spleen,
causes vascular occlusion and inflammation of different organs,
and is related to cerebral malaria [16] and placental malaria [17].
PE sequestration may lead to occlusion of the microvasculature
and thereby contributes to the acute pathology of severe forms of
malaria [18–22].
Distinct domains of different var genes have been shown to bind
specific ligands in vitro. For example, the CIDR1-a domain was
implicated in binding CD36 [23,24]. Different DBL1-a domains
from various PfEMP1 were shown to bind the CR1 receptor on
RBC [10], glycosaminoglycans on RBC, and heparan sulfate on
the endothelial surface [23,25]. The DBLbC2 domain combina-
tion binds ICAM1 [26], and DBLb alone binds PECAM1 [23].
Specific host receptors have been implicated in specific malaria
syndromes (reviewed in [27]). PE sequestration in cerebral
capillaries and venules is a hallmark of cerebral malaria. ICAM1
is expressed at high levels in brains of patients with cerebral
malaria, and has been implicated in this syndrome [28]. Some
DBLbC2 domains of different PfEMP1 proteins bind ICAM1
[26]. In a survey of the entire repertoire of DBLb-C2 domains
PLoS Pathogens | www.plospathogens.org 1 April 2009 | Volume 5 | Issue 4 | e1000386(n=25) from the IT4 line genome [29], 6 domains bound ICAM1.
These studies employed a complex assay based on adhesion of
ICAM1-coated beads to COS-7 cells that express PfEMP1
domains, and manual counting by microscopy. This approach is
semiquantitative, time-consuming, and low throughput.
We have now developed a high throughput DBL domain-
receptor binding assay and used it to study ICAM1 binding to the
DBLbC2 domain repertoire of 3D7 clone parasite. Of the 16
DBLbC2 domains tested, we find that a single domain from a
Group A PfEMP1 protein (PF11_0521) binds ICAM1 strongly.
Our structural analyses suggest that DBL2bC2PF11_0521 binding to
ICAM1 may be due to key conserved residues previously identified
in IT4 line domains. Also, our truncation and binding analyses
suggest that DBLbC2 domain extends about 80 amino acid
residues upstream of its previously suggested boundary [26].
Binding-inhibition studies using our high throughput platform
suggest that neutralizing antibodies may be infrequent in African
children, but are common in immune African adults.
Results
Binding studies
In our expression system, recombinant protein levels can be
monitored during immobilization/purification on immobilized
anti-GFP antibodies by fluorescence, as we previously described
using the multi-well plate format [30]. To immobilize DBLbC2
constructs on BioRad BioPlex beads, we used a similar scheme
here (Figure S1A): anti-GFP antibody was cross-linked to beads of
different fluorescence intensity (i.e., different bead regions), then
bead regions of distinct intensity were incubated with lysates of
COS cells expressing individual domains as GFP-fusion proteins,
and washed extensively for fast immobilization/purification [30].
Domain immobilization was confirmed by reactivity of beads with
biotinylated anti-GFP. Signal intensity was similar for all
constructs (other than mock-transfected cells, data not shown)
indicating saturation of beads with recombinant domains.
In binding assays that used this bead array (Figure S1B), only
the DBL2bC2PF11_0521 domain among the 16 domains tested
bound to ICAM1 at high levels (Figure 1). This result was
reproducible in numerous assays using different preparations of
recombinant domains. We also tested the DBL2bC2PF11_0521
domain and several other non-binding domains using the
traditional multi-well plate format [30], and obtained identical
results (data not shown). In addition, ICAM1-Fc binding to
DBLbC2 domains was detected by anti-human IgG at a nearly
identical level to detection by monoclonal antibody (mAb) RR1
(data not shown), independently confirming the above results.
To confirm the specificity of ICAM1 binding to
DBL2bC2PF11_0521, we tested the well-characterized mAb My13
for its ability to inhibit the interaction. According to earlier studies,
My13 strongly inhibits binding of infected erythrocytes to ICAM1,
but does not block binding of non-inhibitory mAb RR1 to the
ICAM1 molecule [31]. Our results (Figure 2) demonstrate
complete inhibition of ICAM1 binding to DBL2bC2PF11_0521 by
an excess of My13, confirming the specificity of
DBL2bC2PF11_0521-ICAM1 binding in our assay.
Sequence analysis of binding domains
Using CLUSTALW 2.0.5 and subsequent manual curation, we
aligned and analyzed sequences of DBLbC2 domains that bind
and do not bind ICAM1. Figure S2 shows the alignment of
DBLbC2 domains from both FCR3/IT and 3D7 strains, with four
loops predicted to participate in ICAM1 contacts [32] indicated in
boxes. We find that residues previously shown to be conserved in
the ICAM1-binding DBL2bC2 domains of FCR3/IT are
conserved in ICAM1-binding domain of 3D7 as well. The level
of conservation among the residues in or directly adjacent to the
ICAM1-binding structural loops is much higher in the binding
versus non-binding DBLbC2 domains. This may indicate that
these residues have an important role in structure or a direct
interaction with the ligand.
Detailed analysis of the four ICAM1-binding loops revealed
additional conserved residues. In loop 1, a Thr residue in the
middle of the loop is conserved in every ICAM1-binding domain
(and absent in 50% of non-binding domains). In loop 3, a 3-amino
acid motif containing a hydrophilic residue-hydrophobic residue-
hydrophilic residue, is completely conserved in binding domains.
The hydrophobic residue in this motif is Ile with a single
conservative exception (Val in var16), and appears to be in close
contact with the ICAM1 molecule in the model [32]. This residue
is absent in 37% of non-binding sequences. We speculated that
preference in usage of Ile over Val may be explained by slightly
larger surface of Ile in contact with the residues of ICAM1 (Figure
S3A and S3B).
In previous analyses, an Ala or Leu residue was observed in
position 3 of loop 4, in all but one ICAM1 binding domain (the
exception being the FCR3/IT var1 DBL2bC2 domain where His
is present) (Figure S2). In the 3D7 repertoire, 3 other non-binding
domains carry Ala or Leu at this position, in addition to the
ICAM1 binding DBL2bC2PF11_0521 domain. Similarly, in FCR3
strain parasites, 3 non-binding domains carry Ala or Leu at this
position. However, the non-binding domains with the Ala or Leu
residue in loop 4 contain multiple substitutions in other conserved
regions and positions, which may explain their non-binding status.
Generally, ligand interactions involving substantial surfaces of
amino acid residues are not significantly altered by substituting a
single residue that participates in binding, so long as the
substitution fits into the structure without clashes and does not
affect structural integrity (e.g., substitutions in flexible loops) [33].
This was elegantly demonstrated by the Smith group [29], which
examined amino acid substitutions and their combinations on
ICAM1 binding by DBL2bC2 domains from two genes, var16 and
Author Summary
Plasmodium falciparum exports the protein PfEMP1 to the
surface of parasitized erythrocytes for roles in immunoeva-
sion and adhesion. The size and structural complexity of
this diverse protein family have limited earlier studies of
PfEMP1 biology to low throughput and semi-quantitative
approaches. We developed a high throughput quantitative
assay of PfEMP1 adhesion and used it to analyze structural
features of domains that bind the putative cerebral
receptor ICAM1, as well as to survey the acquisition of
functional antibodies in malaria-exposed children and
adults. In studies of the PfEMP1 repertoire of clone 3D7
parasites, a single specific domain bound ICAM1 strongly.
PfEMP1 domains that bind ICAM1 strongly have conserved
features, including conserved amino acids within other-
wise highly variant flexible loops of the protein. While
neutralizing antibodies against the PfEMP1–ICAM1 inter-
action were uncommon in Tanzanian children, such
antibodies were common in east African adults, possibly
explaining why immune adults rarely carry ICAM1-binding
parasites. This high throughput platform will significantly
accelerate studies of PfEMP1 binding domains and the
corresponding antibody responses involved in protective
immunity.
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complexed with ICAM1 [32] and the Deep View/Swiss-pdb
viewer program (v.3.7), we examined the effect of replacing
conserved Ala286 with Tyr in loop 4. The substitution does not
introduce any amino acid residue clashes, and may provide an
additional intra-domain hydrogen bond to R113 (data not shown).
We infer that the loss of binding to ICAM1 is not due solely to
substitutions of Ala or Leu in loop 4, but results from combinations
of substitutions that involve this and other residues in the protein.
We are currently testing this hypothesis using our quantitative
BioPlex approach and site-specific mutagenesis. Other residues
that we predict may have an effect on the domain structure or
ligand binding are indicated in red in Figure S2.
DBL2bC2PF11_0521 N-terminal fragment contributes to
ICAM1-binding activity
Our sequence and binding analyses indicate that structural
DBLbC2 domain is larger than previously suggested [26]. We
propose that the domain starts about 80 aa residues upstream of
the first Cys residue of A4tres DBL2bC2-ICAM1 domain. With
a single exception (var6 from FCR3/IT parasite that preserves
only Cys) this N-terminal region starts with a conserved Asn-Pro-
Cys sequence and contains multiple conserved residues (Figure
S2), independent of the type of domain located upstream of
DBLbC2. With regard to downstream C2 region, our analysis
demonstrates that previously described isolated DBLb domains
Figure 1. ICAM1 binds strongly only to DBL2bC2PF11_0521 domain from the 3D7 DBLbC2 repertoire. (A) Assays using the original panel of
proteins prepared in COS-7 cells. Blue font indicates 5 constructs that were truncated to varying degrees (Figure S2) at their N-terminus in
comparison with the other 11 full-length domains including the active DBL2bC2PF11_0521 domain. (B) Assays using full-length versions of the 5
domains that were prepared as truncated constructs in original panel of proteins. Graphs shown are representative of 3 (A) and 2 (B) independent
experiments performed with different preparations of 3D7 DBLbC2 domains. Bars are averages of duplicate measurements, error bars indicate
standard deviations. Results of all experiments were nearly identical. Red line indicates level of binding with the negative control beads plus 2
standard deviations. AdEx and K – negative controls in which beads were coated with lysates of pAdEx-transfected and mock-transfected COS-7 cells,
respectively.
doi:10.1371/journal.ppat.1000386.g001
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DBL3b in MC var1) are, in fact, DBLbC2 domains with
degenerate C2 as well as upstream N-terminal sequences. These
domains contain easily recognizable C2 features including the Y-
motif and other conserved residues, as well as the upstream N-
terminal fragment described above (Figure S4). A degenerate Y-
motif was previously recognized in DBL6b of FCR3 VAR1CSA
protein [34]. N-terminal and C2 sequences appear to diverge
from the consensus sequence to similar degrees, suggesting a
possible interaction between these fragments in 3-dimensional
structure.
We inferred that the additional N-terminal sequence contrib-
utes to the complete DBLbC2 domains, and tested its effect on
ICAM1-binding activity. We re-cloned DBL2bC2PF11_0521
domain (amino acid residues 1–522 in Figure S2) into pHisAdEx
vector as well as two truncated constructs: one (named N-term)
lacked 32 amino acid residues at the C-terminus (construct ends
with conserved ACNC sequence plus two residues at the C-
terminus), and another one (named C-term) lacked 68 amino
acid residues at the N-terminus (construct starts with conserved
Asn-69 at the N-terminus and includes complete ICAM1
minimal binding domain [34]) (Figure 3). The amount of all
Figure 2. Monoclonal antibody My13 inhibits ICAM1 binding
to DBL2C2PF11_0521. ICAM1 (1 mg/ml) was preincubated with buffer
or various concentrations of mAb My13 and then tested for binding to
DBL2bC2PF11_0521-coupled beads (average of duplicate measurements,
error bars indicate standard deviations). Negative control values (signal
from HisAdEx-coupled beads) were measured simultaneously in the
same wells and subtracted from the signals obtained with
DBL2C2PF11_0521 domain.
doi:10.1371/journal.ppat.1000386.g002
Figure 3. Binding activity and scheme of DBL2bC2PF11_0521 domain and its truncation fragments N-term and C-term. Numbers indicate
amino acid residues according to Figure S2. L1 through L4 indicate positions of flexible loops shown in Figure S2. ‘‘Y’’ indicates position of Y-motif
(Figure S4) and ‘‘YAF’’ indicates position of Y(A/T)F conserved motif in C2 region. Graph demonstrates ICAM1 binding activity (in arbitrary units,
average of duplicate measurements) of DBL2bC2PF11_0521 domain and its truncated variants, N-term and C-term. Error bars indicate standard
deviations. Similar results were obtained in 3 independent experiments.
doi:10.1371/journal.ppat.1000386.g003
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anti-GFP antibody, and all proteins had His-tag at their N-
termini confirmed by reactivity with anti-His antibody (data not
shown). Binding of ICAM1 (Figure 3) clearly indicate that
removal of the N-terminal fragment profoundly reduces ICAM1
binding activity. Since full-length and truncated variants all
demonstrated similar and strong GFP fluorescence, which is a
good indicator of correct folding of the entire membrane protein
[35], our results suggest an important role for the N-terminal
sequence in ICAM1 binding. A similar effect on adhesion was
previously observed earlier in a semi-quantitative assay of the
A4tres DBL2bC2 domain with an N-terminal truncation down
to the first conserved Trp (var31 Trp-106 in Figure S2). This N-
terminal truncation combined with C-terminal truncation up to
the end of Y-motif (var31 His-449 in Figure S2) completely
abolished ICAM1 binding [34].
Binding-inhibition and binding-reversal studies with
human plasma
We tested inhibition of ICAM1 binding to DBL2bC2PF11_0521
domain using pooled human plasma from immune adult males
living in East Africa and from non-immune US adults (Figure 4).
Pooled immune plasma from Africa blocked binding of ICAM1 to
the DBL2bC2PF11_0521 domain by 78%, compared to binding in
NI plasma that did not reduce binding compared to media alone.
However, immune plasma was not efficient (,15% reduced
binding) in assays that measured reversal of adhesion (Figure 4),
indicating a strong association between ICAM1 and the
DBL2bC2PF11_0521 domain with low OFF rate. This result
complements previous data with ICAM1-binding parasites that
demonstrated less than 30% reversal of parasitized erythrocyte
(PE) adhesion with immune sera [36].
To study the acquisition of neutralizing antibodies against the
ICAM1 binding interaction, we assayed plasma samples collected
from infants and toddlers participating in longitudinal birth cohort
studies in Tanzania. Plasma from 7 children that were collected at
several time points between 24 and 148 weeks of age, were tested
for inhibition of ICAM1 binding to DBL2bC2PF11_0521 domain
(Figure 5A). In parallel, we tested reactivity of IgG from the same
plasma to DBL2bC2PF11_0521 domain (Figure 5B). Inhibition of
ICAM1 binding activity was uncommon, and appeared to be
short-lived in at least one child. The IgG reactivity curves appear
almost as mirror images of the ICAM1 binding-inhibition curves
(with the exception of the 148 week time point for the brown line
child, discussed below), suggesting that naturally acquired anti-
DBL2bC2PF11_0521 domain antibodies include at least a fraction of
functional antibodies as they develop in individual children.
We tested levels of neutralizing antibody in additional plasma
samples collected from children during the first 2 years of life,
compared to plasma from adult males, all living in malaria
endemic areas in East Africa (Figure 6). Plasma from most adults
but only a few children contained neutralizing antibodies against
the ICAM1—DBL2bC2PF11_0521 domain interaction, and neu-
tralizing activity was significantly higher in plasma from adults
versus children (P,0.01 when adults were compared to children
24 to 76 weeks old, and P,0.05 when compared to children
100 weeks or older, Kruskal-Wallis test). Neutralizing activity did
not increase significantly in the first 2 years of life, although a
trend to increasing activity was observed after 100 weeks of life.
The same trend appeared in our longitudinal cohort study of 7
patients described above (Figure 5A), with a statistically significant
difference in neutralizing activity between 48 and 148 weeks
(P,0.05 by Kruskal Wallis test with Dunn’s multiple comparison
post-test).
Discussion
PE bind endothelial receptors to sequester in vascular beds, and
PE binding to ICAM1 has been implicated in cerebral malaria. In
this study, we developed a functional BioPlex micro-bead protein
array, and applied it to study ICAM1-binding P. falciparum ligands
and the acquisition of neutralizing antibodies in naturally exposed
individuals. Our results indicate that a single DBL2bC2PF11_0521
domain in the 3D7 genome binds at high levels to ICAM1, and
the corresponding PfEMP1 protein is classified as Group A.
Binding involves an N-terminal region that has not previously
been recognized as an integral part of the DBLbC2 domain. While
immune adults in East Africa commonly display neutralizing
antibodies against this interaction, such antibodies are uncommon
in infants and toddlers in the same region.
Immunological profiling of sera for reactivity against different
antigens is a common method for assessing acquired immunity
and identifying potential vaccine candidates [37]. However,
relating immune responses to malaria resistance is not straight-
forward since exposed individuals are typically infected repeatedly
throughout life, and develop diversified immune responses against
multiple antigens, in many cases without comprehensible rele-
vance to disease severity. Multiple studies have sought to relate
seroreactivity with disease susceptibility in young African children
[38–44], but no candidate antigens for a severe malaria vaccine
have been identified. While seroreactivity studies are useful for
defining the immunoepidemiology of existing vaccine candidate
antigens [30,45], functional assays may be essential for the
discovery of novel vaccine candidates. Functional antibody
responses are likely to be less diverse, to target fewer antigens,
and to have a stronger association to protection from severe forms
of malaria.
In this paper, we describe a high throughput approach to
measure the presence and relative amount of functional antibodies
Figure 4. Pooled immune serum from adults living in a malaria-
endemic area efficiently blocks but poorly reverses ICAM1
binding to DBL2bC2PF11_0521 domain. Blocking of binding:
domains immobilized on BioPlex beads were preincubated with pooled
US non-immune plasma (NI) or pooled immune plasma from adult
patients living in malaria endemic area, then allowed to bind with
ICAM1. Reversal of binding: domains immobilized on beads were
allowed to bind to ICAM1, and then treated with indicated sera. Binding
was normalized to the binding obtained with beads pre-incubated with
buffer before reaction with ICAM1 (100%). Error bars indicate standard
deviations of duplicate measurements. Similar results were obtained in
3 independent experiments.
doi:10.1371/journal.ppat.1000386.g004
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PLoS Pathogens | www.plospathogens.org 5 April 2009 | Volume 5 | Issue 4 | e1000386Figure 5. Inhibition of ICAM1 binding to DBL2bC2PF11_0521 domain by sera obtained from young children living in a malaria-
endemic region is infrequent. Plasma samples collected from children between 24 and 148 weeks of age were used to inhibit ICAM1 binding to
DBL2bC2PF11_0521 domain (A) and to measure the reactivity of plasma IgG to DBL2bC2PF11_0521 domain (B). Levels of binding after incubation with
pooled plasma from non-immune (NI) or immune adults are indicated (thickness of each line corresponds to the standard deviation margin). Different
colors indicate different children donating samples at sequential time points during early life. Error bars are standard deviations of duplicate
measurements for each data point. Similar results were obtained in 3 independent experiments.
doi:10.1371/journal.ppat.1000386.g005
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quantitative and does not allow for high throughput studies [29].
The earlier approach was based on expression of recombinant
PfEMP1 domains on the surface of mammalian cells; incubation of
these mammalian cells with small resin beads chemically cross-
linked to the host cell receptors; removal of unbound beads from
mammalian cells attached to microscope glass by inversion and
gravity sedimentation of unbound beads; and manual counting of
the beads bound to the surface of mammalian cells. The approach
exploited in our work is based on expression of functional antigens
in mammalian cells, and rapid antigen immobilization in a
directed manner on the surface of BioPlex fluorescence-coded
beads. This approach allows multiplexed analyses of protein
features including receptor binding activity (Figure S1) as well as
seroreactivity studies in a high throughput manner.
Our studies focused on the construction of a 3D7 genome-wide
array of the DBLbC2 domain, which was previously shown to
bind ICAM1 in studies of other parasite lines [26,28]. Analysis of
ICAM1-binding activity in this array revealed that only the
DBL2bC2PF11_0521 variant out of 17 domain variants, binds the
receptor at high levels. Alignment of 3D7 ICAM1 binding and
non-binding domains with previously identified ICAM1-binding
domains from other parasite strains revealed new structural
features related to the ICAM1 interaction (Figure S2), in
particular, a conserved Thr residue in loop 1 and a conserved 3-
amino acid motif in loop 3. This analysis further highlighted the
potential role of conserved residues within predominantly non-
conserved flexible loops in adhesion, and, therefore, as targets for
intervention.
All DBLbC2 domains that we tested share highly conserved
structural features, like helices and loops, and therefore, their
general architecture should be similar. Constructs of these
domains used the same boundaries and yielded recombinant
protein at similar levels (according to GFP fluorescence) in a
system that is well-suited for folding of transmembrane disulfide-
rich proteins. Therefore, all recombinant domains have a high
probability of folding similarly well. Because one of DBLbC2
domain variants clearly demonstrated binding activity, we assume
that other variants that did not bind were properly folded but do
not function as ICAM1 ligands. Nevertheless, since every protein
is unique, false negatives can not be excluded completely without
direct proof of correct folding by methods like X-ray or NMR,
which are outside the scope of this study. Our findings also suggest
that the structural/functional DBLbC2 domain involved in
ICAM1 binding includes about 80 amino acid residues upstream
of the previously suggested DBLbC2 domain [26]. This N-
terminal sequence contains an alpha-helix (shown in Figure S4)
predicted by several algorithms [46] in each DBLbC2 domain
described here. Two other short segments associated with
conserved and semi-conserved residues downstream of the
alpha-helix were variously predicted to be alpha-helical or
extended strands (not shown).
This high throughput assay platform can be used to profile
functional antibody levels among naturally exposed children and
adults. We find that antibodies that inhibit ICAM1 binding to
DBL2bC2PF11_0521 appear sporadically in the first 2 years of life
(Figure 5 and 6). Conversely, many immune adults have these
antibodies in their sera. Neutralizing activity in adult plasma did
not correlate with age in this group of adults (18 to 54 years old),
consistent with the solid and stable protective immunity enjoyed
by all adults in these communities. The slow acquisition of
functional antibody may reflect that this domain variant is rare in
the community, that the immature immune system of young
children responds poorly to some PfEMP1, or that some other
host-parasite interaction thwarts the development of functional
immunity. In another study in a malaria endemic area [47], serum
anti-rosetting activity against a particular lab strain (FCR3)
appeared in only about 10% of children 2–5 years old, but in
up to 60% of 15–16 year old adolescents, demonstrating a similar
slow accumulation of functional responses. We do not know at
present whether the functional response (inhibition of ICAM1
binding) is variant-specific. Future studies will clarify this question.
With regard to longevity of the immune response, an earlier
study [48] found that anti-PfEMP1-like responses are short lived
and variant-specific, at least in a low malaria endemicity area. We
observed functional antibody to ICAM1 binding was short-lived in
one child (green line in Figure 5). We are preparing to test whether
this phenomenon is common using a larger set of children’s
plasma collected in longitudinal cohort studies. We will also
examine other features of the natural immune response to malaria,
such as the apparent discordance of seroreactivity and functional
activity observed in some children (brown line in Figure 5). This
may indicate that the amount of non-functional antibodies may
increase without increasing the amount of functional antibodies, or
that non-functional antibodies that increase with time may
successfully compete with functional antibodies and block their
activity. However, this dataset is limited and it would be
premature to make definitive conclusions at present.
Ourhigh throughputapproachwillnowallow ustotestnumerous
additional ICAM1 binding domains, and to determine which of
these is targeted by neutralizing antibodies that also block parasite
binding. With an expanded dataset, we can correlate functional
antibody responses with clinical outcomes in these vulnerable
populations. These future studies will also examine the concordance
between this assay and the traditional binding-inhibition studies
using parasitized red blood cells, including the ability to detect
variant-specific versus broadly reactive functional antibodies.
Figure 6. Anti-adhesion antibodies that inhibit binding of
DBL2bC2PF11_0521 to ICAM1 accumulate with age. Individual
plasma from children of various ages (24 weeks, n=26; 48 weeks,
n=28; 76 weeks, n=23; 100 to 148 weeks, n=10, indicated as $100
wk) or adults (18 to 57 years old, n=33) living in malaria holoendemic
areas, as well as controls (buffer, pooled non-immune (NI) serum, and
pooled male adult serum (Adult pool) from malaria endemic area) were
used to inhibit ICAM1 binding to DBL2bC2PF11_0521. Horizontal bars
indicate median for each group. Similar results were obtained in 2
independent experiments.
doi:10.1371/journal.ppat.1000386.g006
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Ethics statement
Human plasma samples used in these studies were collected from
East African donors under protocols approved by relevant ethical
review committees. Study participants provided written informed
consent before donating samples. Ethical clearance was obtained
from Institutional Review Boards of SBRI and the National Medical
Research Coordinating Committee in Tanzania.
DBLbC2 domain expression constructs
All constructs were cloned into the pAdEx vector described
earlier [30]. Expression of constructs in COS-7 cells and lysate
preparation were also described in [30]. All expressed constructs
are GFP-fusion proteins that contain an extracellular DBLbC2
domain, a short trans-membrane region, and a cytoplasmic
domain fused to green fluorescent protein (GFP). In addition,
full-length and truncated forms of DBL2bC2PF11_0521 domain
were cloned into modified vector pHisAdEx. This vector was
constructed as follows: pAdEx plasmid was digested with SfiI and
BamHI restriction enzymes, then the large fragment was isolated
by agarose gel electrophoresis and ligated with double-stranded
oligonucleotide adaptor prepared by annealing of two oligonucle-
otides 59-GAT CCC TGC GTG GTG GTG GTG GTG GTG
CT-39 and 59-ACC ACC ACC ACC ACC ACG CAG G-39. The
resulting construct was verified by sequencing. Proteins expressed
from this vector are similar to proteins expressed from pAdEx
vector but contain His6-tag at their N-termini. Various PfEMP1
domains that supported binding of ICAM1 (see above) and CD36
(data not shown) in the pAdEx expression system also supported
binding in the pHisAdEx expression system. Primers used for
cDNA amplification using 3D7 genomic DNA are shown in
supplementary Table S1. Alignment of all DBLbC2 domains is
shown in supplementary Figure S2. Five DBLbC2 domains, that
were shorter at their N-termini than other 11 domains after
amplification with primers indicated in Table S1, were also
obtained within the same boundaries as for other domains and
cloned into pAdEx and pHisAdEx for expression. New forward
primers for their PCR amplifications are shown in Table S2.
Preparation of functional DBLbC2 bead array
25 mg of anti-GFP antibody (Rockland, Gilbertsville, PA) was
coupled to 200 ml of each different BioPlex bead region (Bio-Rad)
(19 regions total) as described by the manufacturer, then
resuspended in PBS containing 1 mg/ml BSA, 0.05% Tween-
20, and 0.02% sodium azide (PBS-TBN buffer). Anti-GFP-
coupled beads were incubated for 2 hours at 4uC with COS-cell
lysates containing expressed domains, washed in PBS-TBN, and
used in ligand binding experiments. These beads are designated as
DBLbC2-coupled beads.
DBLbC2 domain–ICAM1 binding and binding-inhibition
assay
All DBLbC2-coupled beads were mixed together in quantities
of ,40–60 beads of each bead region (beads with distinct
fluorescence intensity) per ml. 50 ml of bead mixtures were
transferred into individual wells of HTS 96-well plates (What-
mann) that were pre-incubated with PBS-TBN for 30 minutes.
Beads were washed in wells 3 times with PBS-TBN and incubated
with different concentrations (20 – 0.1 mM) of ICAM1-human Fc
receptor (R&D Systems, Minneapolis, MN). After 1 hour
incubation at room temperature (RT) at constant rotation at
600 rpm, beads were washed in PBS-TBN and incubated in
similar fashion with 1:10 diluted biotinylated anti-ICAM1
monoclonal antibody (mAb) RR-1 (Axxora, San Diego, CA)
followed by 1 hour incubation with 1:250 diluted streptavidin-
phycoerythrin (SA-PE) fluorescent molecules (Jackson ImmunoR-
esearch, West Grove, PA). Also, in some experiments (binding
only, not binding-inhibition by human serum) we used anti-human
IgG coupled to phycoerythrin (1:250 dilution, Jackson ImmunoR-
esearch) to detect bound ICAM1-human Fc and obtained almost
identical results. After a final wash, 96-well plates were transferred
into the BioPlex apparatus (Bio-Rad) to quantify ICAM1 binding
(measured in phycoerythrin channel) to the individual DBLbC2
domains. For negative controls, lysates prepared from mock-
transfected cells, and from pAdEx vector transfected cells, were
also coupled to beads. These control beads were mixed with the
DBLbC2-coupled beads and assayed simultaneously. The pAdEx
vector produces GFP-fusion proteins that contain an irrelevant
peptide of 37 amino acids in the extracellular domain.
To confirm the specificity of ICAM1 binding to
DBL2C2PF11_0521, ICAM1-Fc (1 mg/ml) was incubated with
various concentrations of mAb My13 (Axxora) for 1 hour at room
temperature and then used to bind to the mixture of His-
DBL2C2PF11_0521 and HisAdEx (negative control) coupled beads
as described above using RR1 mAb for detection.
For binding inhibition assays DBLbC2-coupled beads were pre-
incubated for 1 hour at RT with various plasma samples diluted
(1:5) in PBS-TBN. The beads were then assayed in the same
fashion as for the binding assay described above using RR1 mAb
for detection. For binding-reversal assays, the binding assay was
performed as described above, except that the beads were
incubated with various plasma samples diluted (1:5) in PBS-TBN
for 1 hour at RT after the reaction with SA-PE, and then washed
just prior to quantification in the BioPlex apparatus.
Plasma samples
Human plasma samples used in these studies were collected
from East African donors under protocols approved by relevant
ethical review committees. Study participants provided written
informed consent before donating samples, and included adult
males from Kenya [49,50] and children of different ages from
Tanzania [51]. Malaria is endemic in both these regions. Plasma
from 5 randomly selected non-immune donors in the US were
separated from whole blood obtained from commercial sources
(Valley Biomedical) and used in a pool as a negative control.
Reactivity of human IgG with DBL2bC2PF11_0521 domain
DBL2bC2PF11_0521 domain-coupled beads were washed in wells
3 times with PBS-TBN and incubated with children plasma
samples at 1:100 dilution in PBS-TBN. After 1 hour incubation at
room temperature at constant rotation at 600 rpm, beads were
washed in PBS-TBN and incubated in similar fashion with 1:250
diluted anti-human IgG coupled to phycoerythrin (Jackson
ImmunoResearch) for 1 hour. Signal was measured in the BioPlex
apparatus to quantify bound IgG. Signals obtained for beads
coated with protein expressed by pAdEx vector were used as
negative controls and were subtracted from signal obtained with
DBL2bC2PF11_0521 domain-coupled beads. Also, pooled samples
of non-immune US plasma (n=5) and immune plasma from
adults living in malaria endemic region (n=5) were used as
additional negative and positive controls, respectively.
Supporting Information
Figure S1 Scheme of high throughput functional assays based
on BioPlex technology. (A) Scheme of immobilization-purification
of PfEMP1 domains on BioPlex beads. (B) Scheme of detection of
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PLoS Pathogens | www.plospathogens.org 8 April 2009 | Volume 5 | Issue 4 | e1000386receptor-binding domains and inhibition of receptor binding. Up
to 100 different bead regions (colors) each coupled to 1 protein can
be mixed together in 1 well for interaction with ligand. Various
blocking reagents (like antibodies) can be added or pre-incubated
before addition of a ligand. All beads from each well then are
taken up into BioPlex machine, each bead region is classified by
color (1st laser). Simultaneously, signal from detection molecule is
measured by 2nd laser for each bead region (protein).
Found at: doi:10.1371/journal.ppat.1000386.s001 (0.07 MB
DOC)
Figure S2 Alignment of 3D7 DBLbC2 domains and FCR3/IT
DBLbC2 domains. FCR3/IT DBLbC2 domains are designated as
var1 through var44. Numbering of residues begins with the first N-
terminal residue shown in the figure for FCR3/IT domains, or
with the first residue of the recombinant 3D7 domains used for
assays in this study. All 3D7 domain sequences contain the
minimal binding region identified previously in a semi-quantitative
assay [34]. Highlighted in gray - domains that do not bind ICAM1;
highlighted in dark gray - sequences that were missing from the
constructs initially assayed in this work and presented in Figure 1A,
they were included in constructs and tested for ICAM1 binding as
described in Figure 1B; highlighted in yellow - non-binders with Ala
or Leu in position 3 in flexible loop 4 (discussed in text); highlighted
in green-blue - N-terminal residue and C-terminal residue of
minimal var31 constructs that bind ICAM1 in semi-quantitative
assay [34]. Color font: Purple - conserved and semi-conserved
residues, bold font indicates predominant residue; Blue - conserved
and semi-conserved residues in ICAM1 binders, bold font indicates
residues only in ICAM1 binders for emphasis; Red - amino acid
residue substitution with significantly different physical-chemical
character that may affect structure or/and function of the domain;
Green - the only exception for position 3 in loop 4 in ICAM1-
binding variant; Pink - amino acid residues that differ from the
annotated sequence in PlasmoDB database. Red rectangles indicate
four flexible loops involved in ICAM1 binding according to the
modeling studies [32].
Found at: doi:10.1371/journal.ppat.1000386.s002 (0.19 MB
DOC)
Figure S3 Model of Ile and Val amino acid residues in ‘‘loop 3’’
of DBLbC2 domain interacting with ICAM1. Illustration of
interaction and amino acid residue substitution were created using
DBLbC2::ICAM1 complex modeled in [32] and Deep View/
Swiss-pdb viewer program (v.3.7). Green - DBLbC2 domain,
yellow - ICAM1 molecule. ICAM1 residues within 5 angstrom
distance from Ile/Val residue of DBLbC2 domain shown in
spacefill shape.
Found at: doi:10.1371/journal.ppat.1000386.s003 (0.31 MB
DOC)
Figure S4 Alignment of two DBLbC2 domain sequences
(bottom) and three DBLb domain sequences (previously described
as lacking adjacent C2 domains) with surrounding sequences (top).
Color font: Orange - cysteines not present in any sequence in
Figure S2, which may be involved in disulfide bonding. Other
letter colors are as in Figure S2. Gray highlights indicate extra N-
terminal and C2 domain sequences. Yellow highlight within C2
domain indicate ‘‘loop 4’’ sequence. The results demonstrate that
all sequences share C2 and additional N-terminal sequence
(discussed in the text) with multiple conserved residues. Green
highlight above the sequence alignment indicates alpha-helix
predicted for all (n=36) DBLbC2 domains described in this work
[46].
Found at: doi:10.1371/journal.ppat.1000386.s004 (0.06 MB
DOC)
Table S1 Primers for PCR amplification of 3D7 DBLbC2
domains.
Found at: doi:10.1371/journal.ppat.1000386.s005 (0.05 MB
DOC)
Table S2 Forward primers for PCR amplification of five 3D7
DBLbC2 domains in the same boundaries as active
DBL2bC2PF11_0521 domain.
Found at: doi:10.1371/journal.ppat.1000386.s006 (0.03 MB
DOC)
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